Articles tagged with Anticoagulants
A recent study found that uninterrupted treatment with dabigatran before, during, and after atrial fibrillation ablation significantly reduced the incidence of major bleeding events compared to warfarin. The trial showed a 5.3% reduction in major bleeding events, with major bleeds occurring in 1.6% of patients receiving dabigatran.
A recent study by University of Utah Health investigators found that up to three-quarters of surgery patients may not need anti-clotting medications, which could lead to harm. High-risk patients, however, showed significant benefits from the treatment.
A new analysis found that restarting dabigatran after a major bleeding event leads to lower recurrent hemorrhage risk compared to warfarin. Resuming anticoagulation therapy also reduced the likelihood of stroke-free survival, with dabigatran associated with nearly half the risk of another major bleeding event within one year.
A new study found that oral thrombin inhibitors (OTIs) encourage blood clotting under flowing conditions, increasing the risk of heart attack. The researchers suggest considering this when designing individual therapies for patients taking OTI drugs.
Researchers found that short episodes of atrial fibrillation are associated with a low risk of stroke and other cardiovascular complications. Patients experiencing only brief episodes of the condition were at no greater risk than those without atrial fibrillation, suggesting that anticoagulants may not be necessary in this group.
A new clinical decision rule, HERDOO2, has been validated in the REVERSE II trial, enabling the identification of women at low risk for recurrent venous thromboembolism who can safely discontinue anticoagulants. The study found that over half of these women could stop taking anticoagulants without increasing their risk.
A large-scale clinical trial found that non-vitamin K antagonist oral anticoagulants (NOACs) can be safely used as an alternative to warfarin before cardioversion in atrial fibrillation patients. Edoxaban was shown to be equally effective as current use of warfarin, and expedited the process from initial standard treatment.
A study of over 43,000 patients with atrial fibrillation found that new oral anticoagulants (NOACs) provided similar stroke prevention to warfarin, but caused fewer bleeding incidents. NOACs were associated with a lower risk of intracranial bleeding, particularly when compared to warfarin.
A study published in JAMA found that only 34% of patients with stable INR values while taking warfarin remained stable over the subsequent year, indicating that predicting stability is difficult. Non-vitamin K oral anticoagulants may offer improved safety and efficacy but are more costly.
A study published in Journal of the American College of Cardiology found that more than one-third of atrial fibrillation patients with an intermediate-to-high-risk of stroke are prescribed aspirin instead of oral anticoagulants. This discrepancy may be due to misconceptions about aspirin's efficacy compared to oral anticoagulants.
A study found that patients with atrial fibrillation (AF) at highest stroke risk are often not prescribed the recommended oral anticoagulant therapy. The study included over 429,000 AF patients and found that only less than half of high-risk patients received an oral anticoagulant prescription.
A European Heart Rhythm Association/European Society of Cardiology survey found that patients with no schooling missed treatment targets more often and were less aware of bleeding risks. The study highlights the importance of providing user-friendly education about risk factors for stroke and adequate use of anticoagulants.
Research shows that stroke patients who use mail-order pharmacies have higher medication adherence rates compared to those filling prescriptions at local pharmacies. Medication non-adherence is a significant concern in stroke care, and this study highlights the potential benefits of mail-order pharmacy services.
Researchers found that asymptomatic AF doubles the risk of stroke and premature death compared to age and gender matched people without AF. Treating asymptomatic AF with anticoagulants can nearly completely reverse the increased risk of stroke.
The new guideline aims to standardize the management of iliofemoral deep vein thrombosis (DVT) in Canada, providing a practical approach for physicians. The guideline recommends anticoagulants for all patients with DVT, as well as clot removal and compression therapy for those at high risk of bleeding.
More adults are visiting doctors for anticoagulant treatment due to the popularity of new direct oral anticoagulants (DOACs), which have fewer food and drug interactions than warfarin. The study found that DOACs have risen to nearly match the use of warfarin, with 57% of anticoagulant visits related to warfarin use in 2014.
For individuals over 75, taking newer anticoagulant medications dabigatran or rivaroxaban increases the risk of gastrointestinal (GI) bleeding by 3-5 times compared to warfarin. The study found that younger patients have a lower risk of GI bleeding with these medications.
A study found that appropriate patient selection and pharmacist-led monitoring are associated with higher adherence rates to dabigatran. Modifiable site-level practices, such as collaboration between pharmacists and clinicians for nonadherent patients, also improved adherence rates.
A novel anti-clotting therapy was compared to established anticoagulants in a Phase III trial, but showed similar efficacy and higher moderate to severe bleeding rates, leading to its early termination due to allergic reactions.
Researchers found a conclusive link between genetic variants and increased bleeding risk with warfarin treatment. Patients with specific genetic differences benefit from alternative anticoagulants like edoxaban, offering improved safety and efficacy.
The new guidelines increase the proportion of AFib patients recommended for drug therapy by 19%, particularly affecting women and people over 65, who now have a lower age threshold for stroke risk assessment.
Despite effective oral anticoagulant use, atrial fibrillation patients experience high one-year mortality and morbidity. Statins were found to reduce mortality by one-third, while diuretics increased it by 70%. Hospital readmissions are common, often due to AF or heart failure.
The European Society of Cardiology publishes first recommendations on new oral anticoagulants for pulmonary embolism. The guidelines provide detailed recommendations on drug use and risk stratification, including age-adjusted D-dimer cut-offs.
A new study published in Circulation found that low-dose aspirin significantly reduces the risk of new venous blood clots and cardiovascular events. The treatment is especially useful for patients who cannot take long-term anticoagulant medications due to expense or bleeding risks.
A study analyzed all trials to date, finding that bivalirudin-based regimens increase the risk of heart attacks and stent thrombosis, while heparin-based regimens decrease bleeding risk. The magnitude of benefit was attenuated when glycoprotein IIb/IIIa inhibitor use was similar in both arms.
Anticoagulant-associated intracerebral hemorrhage (AAICH) poses a significant challenge, with a mortality rate as high as 42.3% to 67%. The latest supplement from the Journal of Neurosurgery provides evidence-based guidelines and strategies for managing patients with AAICH.
The review provides guidance on managing surgical patients taking new oral anticoagulants, including discontinuation before procedures and resuming after procedures, as well as dose reductions based on kidney function and liver dysfunction considerations.
A study published in GIE: Gastrointestinal Endoscopy found that cold snare polypectomy significantly reduces the risk of delayed bleeding in patients taking anticoagulants. The procedure outperformed conventional polypectomy in removing small colorectal polyps without causing significant harm to submucosal vessels.
The updated guideline recommends oral anticoagulants for people with nonvalvular atrial fibrillation to prevent stroke. The new drugs are at least as effective as established treatment and have a lower risk of bleeding, making them suitable for many previously undertreated patients.
A large Danish study found that anticoagulant medicine significantly reduces the risk of serious brain damage or death due to a stroke in patients with atrial fibrillation. The study, which followed over 11,000 patients, also showed that mortality within 30 days is lower for those receiving treatment.
Atrial fibrillation management remains suboptimal in Europe, with low adoption of new oral anticoagulants (NOACs) and inconsistent treatment guideline adherence. The pilot registry found that oral anticoagulant use has increased, but NOAC use is still limited, particularly among females.
Researchers developed new methods for synthesizing coumarin-based drugs, which showed promise as anti-inflammatory agents. The study revealed one of the pathways in which coumarins act, and understanding this pathway may help develop future treatments for chronic inflammation diseases.
A new strategy for emergency anticoagulant treatment has been developed, using bivalirudin, which reduces the risk of death or serious bleeding by 8.5%, compared to traditional heparin treatment. The EUROMAX clinical trial found that this approach improves patient outcomes without increasing the risk of stent thrombosis.
A new study by Joyce You found that newer anticoagulants are more cost-effective than warfarin when patients' therapeutic ranges drop below 60%. Warfarin is most cost-effective when patients are within the successful range for more than 70% of the time. The study's results have implications for clinicians and policymakers.
The study found that edoxaban was non-inferior to warfarin in treating VTE, but efficacy was superior in patients with pulmonary embolism and right ventricular dysfunction. Edoxaban also showed reduced bleeding rates in high-risk sub-groups.
A study published in the Journal of the American Medical Association found that otamixaban, a novel anticoagulant, did not reduce ischemic events but increased bleeding among patients with non–ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention (PCI). The trial compared otamixaban with unfraction...
The ISSUE III registry study found that cardiac pacing is more effective in patients with presumed neurally mediated syncope (NMS) and asystolic episodes, than in patients with positive tilt table testing. The registry showed that oral anticoagulation therapy is now widely used in patients with atrial fibrillation.
Patient satisfaction increased significantly using a pharmacist-directed anticoagulation service, with notable improvements in information communication and care quality. The study found a 10.6% rise in overall satisfaction and a 29.5% increase in satisfaction with pharmacist responses.
Two new papers highlight the risks of dabigatran etexilate (Pradaxa) in cases of closed head injuries, showing a higher mortality rate and increased risk of hemorrhage progression. The studies emphasize the need for effective anticoagulation reversal protocols to improve patient outcomes.
The ESC guide offers practical advice on using new oral anticoagulants (NOACs) to prevent stroke in patients with non-valvular atrial fibrillation. It highlights the benefits of NOACs, including reduced monitoring requirements and lower bleeding risk compared to vitamin K antagonists.
Researchers have deciphered the mechanism of anophelin's interaction with thrombin, a key enzyme in blood coagulation. This discovery opens the door to designing new anticoagulant drugs with improved efficacy and reduced side effects, as well as fighting against malaria by developing inhibitors for this substance.
A recent study suggests that some blood clots identified by sensitive testing methods may not require treatment, potentially reducing risks of bleeding complications. However, developing guidelines to accurately identify patients who can benefit from anticoagulant therapy is crucial.
The WOEST study reveals that omitting aspirin in patients treated with oral anticoagulants and having a coronary stent is safe. Results show less bleeding and lower mortality rates compared to traditional triple therapy. This finding has significant implications for future treatment guidelines.
A study published in JAMA found that older women with atrial fibrillation have a significantly higher risk of stroke compared to men, even when taking anticoagulant medication. The research suggests that current stroke prevention therapy may not be sufficient for these patients, highlighting the need for targeted treatment strategies.
Researchers found that lower doses of clot-busting drug tissue plasminogen activator (t-PA) effectively dissolve clots in patients with moderate pulmonary embolism, leading to earlier hospital discharge and reduced complications. Eighty percent of pulmonary embolism patients could benefit from this treatment.
A study found that administering a bolus dose of the anticoagulant drug abciximab directly into the coronary artery involved in causing a heart attack resulted in a significant reduction in heart muscle damage at 30 days. However, manual thrombus aspiration did not produce similar results.
Research found that higher CHADS2 scores are associated with increased risks of stroke, systemic embolism, and major bleeding in A-Fib patients taking oral anticoagulants. Additionally, a study on warfarin patients suggests a 12-week monitoring interval is non-inferior to the current four-week schedule.
A pilot study found Angiomax to significantly reduce major bleeding events in patients with severe aortic stenosis, compared to heparin treatment. The anticoagulant showed a 60% reduction in major bleeding events.
Research finds UK doctors are underdiagnosing and undertreating atrial fibrillation, a major risk factor for stroke, despite improvements in stroke prevention. The study analyzed data from the General Practice Research Database and found that only one in four patients with AF were prescribed preventive anticoagulant treatment.
A new study of over 26,000 stroke patients found that those with Atrial Fibrillation have a mortality rate almost twice that of other stroke patients. The study highlights the need for better use of existing anticoagulant medication to prevent fatal and disabling strokes.
A pharmacist-directed anticoagulation service improves the transition of care for patients treated with warfarin, enhancing communication between hospital and outpatient clinicians. The study found a 5% decline in bleeding and thrombosis risk for patients treated by the service.
Researchers found that mice lacking fibrin showed dramatically decreased survival and increased bacterial loads during gram-negative sepsis. Fibrin helps protect bodies during infection, and its regulation may hold the key to preventing organ failure in sepsis patients.
A new report identifies several synergistic steps to improve AF management, including detecting risk factors, using new antithrombotic therapies, early arrhythmia detection, and timely rhythm control treatment. The report highlights the need for more research into genetic biomarkers to assess AF risk.
Scientists seek to create rat poisons that specifically target rats without posing a threat to people, pets, or wildlife. Researchers are working on tracking rodent consumption and studying resistance mechanisms to develop safer alternatives.
Research from the University of Cincinnati and Massachusetts General Hospital found that warfarin, a common anticoagulant, may not be suitable for all atrial fibrillation patients due to declining stroke risk. The study suggests that treatment guidelines should consider individual patient risks and benefits.
A large study found that men with localized prostate cancer who take aspirin with radiation therapy or surgery have a lower risk of dying from the disease. The use of anticoagulants reduced the risk of death by 6 percentage points, from 10% to 4%, at 10 years.
A recent study published in JAMA found that using lower doses of heparin during coronary procedures does not significantly reduce the risk of major bleeding. The research involved 2,026 patients and compared two dose regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients.
The analysis of the RELY trial found that local standards of care significantly affect the benefits of switching to new treatments, particularly for stroke prevention. In centers with poor INR quality control, dabigatran showed greater advantages over warfarin in preventing stroke and cardiovascular events.
A study of young women with antiphospholipid syndrome reveals a significantly increased risk of stroke and heart attack, particularly when combined with smoking and oral contraceptive use. The findings emphasize the need for screening and warning young women about these cardiovascular risks.
The RE-LY study found dabigatran to be more effective than warfarin in preventing stroke in patients with atrial fibrillation. The higher dose of dabigatran significantly reduces stroke risk by 34% compared to warfarin, while the lower dose has a similar effect but with less major bleeding.